Pharmaceutical Chemistry, North-West University, Private Bag 6001, Potchefstroom 2520, South Africa.
Eur J Med Chem. 2011 Oct;46(10):5010-20. doi: 10.1016/j.ejmech.2011.08.008. Epub 2011 Aug 11.
A series of polycyclic fluorescent ligands were synthesised and evaluated in murine striatal synaptoneurosomes for N-methyl-D-aspartate receptor (NMDAR) mediated calcium flux inhibition and inhibition of calcium influx through voltage gated calcium channels (VGCC). Amantadine (a) and N-(1-adamantyl)-1,3-propanediamine (c) substituted with 1-cyanoisoindole (3), indazole (5), dinitrobenzene (7, 8), dansyl (9, 10) and coumarin (11) moieties showed moderate to high inhibition of the NMDAR. A high degree of VGCC inhibition was observed for the cyanoisoindole compounds (3, 4) the dansyl compounds (9, 10) and the coumarin compound (12). Fluorophores conjugated to hydroxy-4-aza-8-oxoheptacyclotetradecane (13, 14) did not exhibit any significant VGCC inhibition, but the indazole conjugate (14) showed promising NMDAR activity. Dose response curves were calculated for selected NMDAR inhibitors (8-11) and N-[3-(1-adamantylamino)propyl]-5-dimethylaminonaphthalene-1-sulfonamide (10) exhibited the highest activity of the novel compounds. Compound 10 was further used as a fluorescent NMDAR ligand in a fluorescent competition assay utilizing MK-801, NGP1-01 and amantadine as known NMDAR inhibitors to demonstrate the possible applications of the novel fluorescent compounds. These small molecule fluorescent ligands can be considered as possible pharmacological tools in assay development and/or other investigations in the study of neurodegeneration.
一系列多环荧光配体被合成并在鼠纹状体突触小体中进行评估,以评估其对 N-甲基-D-天冬氨酸受体 (NMDAR) 介导的钙流抑制和电压门控钙通道 (VGCC) 钙内流抑制的作用。金刚烷胺(a)和 N-(1-金刚烷基)-1,3-丙二胺(c)取代 1-氰基异吲哚(3)、吲唑(5)、二硝基苯(7、8)、丹磺酰基(9、10)和香豆素(11)部分显示对 NMDAR 的中等至高抑制作用。氰基异吲哚化合物(3、4)、丹磺酰基化合物(9、10)和香豆素化合物(12)对 VGCC 的抑制作用较高。与羟基-4-氮杂-8-氧杂十七环四氢呋喃(13、14)共轭的荧光团没有显示出任何显著的 VGCC 抑制作用,但吲唑共轭物(14)显示出有前途的 NMDAR 活性。对选定的 NMDAR 抑制剂(8-11)进行了剂量反应曲线计算,N-[3-(1-金刚烷基氨基)丙基]-5-二甲基氨基萘-1-磺酰胺(10)显示出新型化合物中最高的活性。进一步将化合物 10 用作荧光 NMDAR 配体,在荧光竞争测定中利用 MK-801、NGP1-01 和金刚烷胺作为已知的 NMDAR 抑制剂,以证明新型荧光化合物的可能应用。这些小分子荧光配体可以被认为是在测定发展和/或其他神经退行性疾病研究中的潜在药理学工具。